Study Title
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Protocol ID
CA045020 / NKTR-214
Disease (Sub Disease)
All tumour types
Diagnosis Stage
Relapsed/refractory
Sponsor
Bristol-Myers Squibb
Collaborators
Nektar Therapeutics
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 30 years
International registry ID's
NCT04730349
| Study Title | Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) |
|---|---|
| Protocol ID | CA045020 / NKTR-214 |
| Disease (Sub Disease) | All tumour types |
| Diagnosis Stage | Relapsed/refractory |
| Sponsor | Bristol-Myers Squibb |
| Collaborators | Nektar Therapeutics |
| Links | https://clinicaltrials.gov/ct2/show/NCT04730349 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 15/04/2021 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 30 years |
| International registry ID's | NCT04730349 |